Nick Urban is an Associate in the Antitrust practice group. He concentrates his practice in the area of complex antitrust litigation.
Mr. Urban focuses on antitrust class actions alleging that pharmaceutical manufacturers wrongfully kept less expensive generic drugs off the market, in violation of the antitrust laws. These cases include In re Namenda Direct Purchaser Antitrust Litigation, No. 1:15-cv-07488 (S.D.N.Y.) ($750 million settlement); In re Modafinil Antitrust Litigation, 2:06-cv-01797 (E.D. Pa.) ($512 million settlement with three of five defendants); In re Aggrenox Antitrust Litigation, 3:13-cv-01776 (D. Conn.) ($146 million settlement); In re Skelaxin (Metaxalone) Antitrust Litigation, 1:12-md-02343 (E.D. Tenn.) ($73 million settlement); In re Wellbutrin XL Antitrust Litigation, 2:08-cv-02431 (E.D. Pa.) ($37.5 million settlement with one of two defendants); In re: Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litigation, 1:18-md-02819 (E.D.N.Y.); In re Niaspan Antitrust Litigation, 2:13-md-02460 (E.D. Pa.); King Drug Company of Florence, Inc. et al., v. Abbott Laboratories et al, 2:19-cv-3565 (E.D. Pa.); and In re EpiPen Direct Purchaser Litigation 0:20-cv-00827 (D. Minn.).
He has also devoted significant time to antitrust cases brought against the banking industry. E.g., Ross and Wachsmuth v. American Express Co., et al., 04-CV-5723 (S.D.N.Y.) ($49.5 million settlement); and Ross, et al. v. Bank of America, N.A. (USA), et al., 05-CV-7116 (S.D.N.Y.) (obtained settlements with four of the nation’s largest card issuers (Bank of America, Capital One, Chase and HSBC) to drop their arbitration clauses for their credit cards for 3.5 years).
While at the University of Pennsylvania Law School, Mr. Urban served as senior editor for the Journal of Law and Social Change and worked at several organizations dedicated to increasing the availability of quality affordable housing through impact litigation and development. Prior to attending law school, he worked as an anti-hunger advocate in the San Diego region and also worked for the Office of the Secretary of State of California.
In the News
- Berger Montague’s Namenda Case Team Honored at the American Antitrust Institute’s 2020 Antitrust Enforcement Awards
- Berger Montague Seeks Preliminary Relief on Behalf of Individuals Who Did Not Receive Federal Coronavirus Relief Payments for Their Dependent Children and Have Urgent Need
- Four Berger Montague Attorneys Honored at the American Antitrust Institute’s 2019 Antitrust Enforcement Awards
- $512M settlement granted final approval in pay-for-delay litigation over Cephalon’s narcolepsy drug Provigil.